Trial Information
GIMEMA Guidelines for the Treatment of Adult ALL Affected Patients at Diagnosis
Inclusion Criteria:
- Diagnosis of acute lymphoblastic leukemia (ALL)
- Negative myeloperoxidase stain
- Phenotype T (ALL-T) and B(ALL-B)
Exclusion Criteria:
- Creatinine > 2.5mg/dL after adequate hydratation
- LVEF <50%
- Presence of documented infections not responding to antibiotic and/or antifungal
therapy
- Presence of concomitant malignant diseases
- Absence of any psychological condition that does not allow to intake high doses of
cortisone
- Patients who have received any antineoplastic chemiotherapy for more than 5 days
- Patients who have received any steroids for more than 10 days
Type of Study:
Interventional
Study Design:
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Principal Investigator
Franco MANDELLI, Pr
Investigator Role:
Principal Investigator
Investigator Affiliation:
Università degli Studi di Roma "La Sapienza"
Authority:
Italy: The Italian Medicines Agency
Study ID:
LAL2000
NCT ID:
NCT00537550
Start Date:
July 2000
Completion Date:
June 2006
Related Keywords:
- Leukemia, Lymphocytic, Acute
- ALL
- Adult
- Leukemia
- Leukemia, Lymphoid
- Precursor Cell Lymphoblastic Leukemia-Lymphoma